Jon has held posts in academia as a member of scientific staff in the Biochemistry Department, Imperial College and then as a Senior Scientific Officer with the Medical Research Council. Jon joined Cambridge Antibody Technology (CAT) in 1992 as a Senior Scientist. Working initially on several drug discovery projects using phage display of antibodies, Jon eventually moved across to operational management. Jon most recently held the post of VP Site General Manager at what is now MedImmune, a wholly-owned subsidiary of AstraZeneca formed through the merger of CAT and MedImmune Inc.
Jon’s responsibilities included leading the site operations of the Cambridge R & D facilities, with specific responsibility for specialist scientific services teams, property, engineering, laboratory and office facilities, security, EHS, procurement, risk management and IT.
Jon sat on the Cambridge site leadership team and the global Medimmune Biotech Operations Leadership team.
Jon is also currently Chairman of the Board of One Nucleus and is vice chair Pharmaceutical Industry Security Forum and chair of the advisory board for Horus, a security consultancy. Jon has a MPhil in cellular pathology, is a Chartered Biologist, a Fellow of the Royal Society of Biology, Follow of the Royal Society of Arts and Manufacturing, and Fellow of the Institute of Directors.